Group items tagged

United States Biopsy Market will cross US$ 17 Billion by the year 2024 owing to the rising prevalence of cancer in the region. According to the World Health Organization, cancer cases are expected to surge 57% worldwide in the next 20 years. Biopsies are most often done to look for cancer; a biopsy is a sample of tissue taken from the body in order to examine it more closely. Further, growing patient awareness and the advancement in the biopsy techniques are also expected to fuel future growth of biopsy market in United States.

Lung biopsy helps in detecting the stages of cancerin patients;thus, increasing the demand for biopsies across the world as it is an important tool for diagnosis and treatment. Biopsy followed by imaging tests helps in determining whether the nodule is cancerous or non-cancerous. As per WHO, in 2018, lung cancer is responsible for the largest number of deaths approximately 1.8 million deaths across the globe because of the poor prognosis for this cancer. Lower respiratory infections remained the deadliest communicable disease, causing 3.0 million deaths worldwide in 2016.

Liquid biopsy, a minimally invasive cancer diagnostic tool, has gained momentum in the last five years due to its advantages over the archaic painful procedure of solid tumour biopsy.

Researchers from the Abramson Cancer Center of the University of Pennsylvania have found that liquid biopsy can help to predict the prognosis of glioblastoma(GBM), the most aggressive and common brain cancer in adults.

Bleeding in semen caused by medical procedures, also known as hematospermia. Blood in semen caused by infections, tumors, and stones in organs as well as anatomical problems. The most common cause is a prostate biopsy.

Single-use medical device reprocessing refers to cleaning, disinfection, testing, sterilization, and remanufacturing of a used medical device to be put in service again. The reuse of single-use medical devices first began in the late 1970s. According to the Centers for Disease Control and Prevention (CDC), around 20 to 30% of the U.S. hospitals reported having reused at least one type of single-use device. The reuse of single-use devices involves ethical, regulatory, legal, medical, and economic issues, which have faced controversy in the last two decades. The reuse of single-use medical devices has increased typically due to the COVID-19 pandemic outbreak. In general, there are two categories of products that can be reused: active and inert. Active products are required for making new products, while inert products are used for making old products stronger, newer, longer-lasting, and more effective. The useful products that are generated are called inert products. These are products that have a certain amount of value because of their function. They are available in different forms like paper, paperboard, metals, plastic, etc. These products can either be reclaimed from the environment, or produced by industries and used for manufacturing purposes. The mobile devices that need to be recycled for single-use medical device reprocessing include diagnostic devices, sterilization equipment, biopsy instruments, blood glucose analyzers, blood pressure monitors, disposable gloves, medical imaging devices, and many more. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/single-use-medical-device-reprocessing.html

Multiple myeloma is a type of cancer that forms a type of white blood cell called a plasma cell. In multiple myeloma, cancerous plasma cells gather around the bone marrow and crowd out healthy cells. Some of the most common symptoms of multiple myeloma are pain in the back or bones, anemia, fatigue, and kidney damage. Multiple myelomas can be identified by a biopsy, which is conducted when tissue samples from the affected area are taken and examined under a microscope. When multiple myelomas are detected on an examination, it is typically very easy to remove them with a scalpel, and in many cases, surgeons will opt to remove only one lobe of tissue at a time. There has the development of various multiple myeloma drugs over the years with key industry players being involved in continuous research and development activities. Selinexor is one of the latest U.S. FDA-approved drug for multiple myeloma and is used to treat people suffering from relapsed or refractory disease. Furthermore, Ixazomib is the first and only oral proteasome inhibitor, indicated for multiple myeloma treatment. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/multiple-myeloma-drugs-are-getting.html

Hereditary Angioedema is a disease, which is the result of genetic mutation, within the families with higher genetic activity. It is not contagious to others. The cause of heredity is still unknown but it is believed that the disease is related to the immunological mechanism. Hereditary Angioedema is a chronic non-inflammatory disease that affects millions of people around the world. Symptoms include persistent dryness of the skin, scalp itching, inflammation, rash, severe skin peeling and cracking, bleeding and hives, pain in the area where the skin is affected. As a part of the diagnosis, a medical practitioner who is experienced in treating hereditary angioedema must do a skin biopsy to find out the exact cause of allergic skin reaction. Rising awareness regarding hereditary angioedema is expected to drive growth of the global hereditary angioedema market during the forecast period. Hereditary angioedema or also referred to as HAE has received significant attention in the recent past as government and non-government organizations across the globe are focused on increasing public awareness to improve diagnosis and enhance the treatment. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/hereditary-angioedema-market-to-witness.html